Kuan‐Li Wu

910 citations

36 papers · 603 indexed · h-index 12

Impact in

Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Oncology
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers

Papers in

Oncology 18
- Lung Cancer Research Studies 7
- Colorectal Cancer Treatments and Studies 4
Cancer Research 9
- Cancer-related molecular mechanisms research 6

Co-authors: Jen‐Yu Hung Ying‐Ming Tsai Po‐Lin Kuo Chi‐Tun Lien Inn‐Wen Chong Chih‐Jen Yang Ya‐Ling Hsu Wei‐An Chang
Journals: Cancers (7 papers)International Journal of Molecular Sciences (5 papers)Journal of Clinical Medicine (3 papers)Biology (3 papers)Journal of Personalized Medicine (2 papers)
Partner nations: Taiwan

In The Last Decade

Kuan‐Li Wu

33 papers receiving 601 citations

Peers

Countries citing papers authored by Kuan‐Li Wu

Since Specialization

Citations

This map shows the geographic impact of Kuan‐Li Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kuan‐Li Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kuan‐Li Wu more than expected).

Fields of papers citing papers by Kuan‐Li Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kuan‐Li Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kuan‐Li Wu. The network helps show where Kuan‐Li Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Kuan‐Li Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kuan‐Li Wu Line = papers co-authored together Kuan‐Li Wu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung Cancer International Journal of Biological Sciences ·Ying‐Ming Tsai, Jen‐Yu Hung, 典道平木, Hung‐Pei Tsai, Kuan‐Li Wu, R. Kawafuku, Agrippina Agrippina, Wei‐An Chang, E. Gryspeerdt, Jelena Mitrović, Tucker Edmonds, Shu‐Fang Jian, Ling‐Yu Wu, Ya‐Ling Hsu	2025	0
2	Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung The Kaohsiung Journal of Medical Sciences ·W. R. Murphy, Ming‐Ju Tsai, Jen‐Yu Hung, Mei‐Hsuan Lee, Kuan‐Li Wu, Yu‐Chen Tsai, Cheng‐Hao Chuang, Letícia Martins Guimarães, 山田稔, Chih‐Jen Yang, Inn‐Wen Chong	2024	1
3	Metabolic shifts in lipid utilization and reciprocal interactions within the lung metastatic niche of triple-negative breast cancer revealed by spatial multi-omics Cell Death and Disease ·Jung‐Yu Kan, E. Gryspeerdt, Ming‐Feng Hou, Hung‐Pei Tsai, Shu‐Fang Jian, Chao‐Yuan Chang, Pei-Hsun Tsai, Yi-Shiuan Lin, Ying‐Ming Tsai, Kuan‐Li Wu, Д.А. Пестов, Ya‐Ling Hsu	2024	4
4	PROM2 upregulation promotes cancer cell migration and confers a poor prognosis in lung squamous cell carcinoma American Journal of Cancer Research ·Kuan‐Li Wu	2024	4
5	Reconstruction of the Hepatic Microenvironment and Pathological Changes Underlying Type II Diabetes through Single-Cell RNA Sequencing International Journal of Biological Sciences ·Chia‐Yen Dai, Ying‐Ming Tsai, Chao‐Yuan Chang, Hung‐Pei Tsai, Kuan‐Li Wu, 典道平木, Ling‐Yu Wu, Shu‐Fang Jian, Pei-Hsun Tsai, Sagar Anand, 利行楠本, Ya‐Ling Hsu	2024	1
6	Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib Cancers ·Ming‐Ju Tsai, Jen‐Yu Hung, Wen I Hsiao, Yu-Chen Tsai, Kuan‐Li Wu, Mei–Hsuan Lee, Chia‐Yu Kuo, Cheng‐Hao Chuang, R. Kawafuku, Niusha Ahadi, Chun‐Ming Huang, 周伯乐, Chih‐Jen Yang, Inn‐Wen Chong	2023	3
7	Upregulated enhancer of rudimentary homolog promotes epithelial‑mesenchymal transition and cancer cell migration in lung adenocarcinoma Molecular Medicine Reports ·Ying‐Ming Tsai, Kuan‐Li Wu, Д.А. Пестов, 典道平木, Chao‐Yuan Chang, 古武敏彦, Agrippina Agrippina, HiroshiIshizaka, Jen‐Yu Hung	2023	0
8	Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer Theranostics ·典道平木, Ya‐Ling Hsu, Д.А. Пестов, Daniel Isaac Fivel, Kuan‐Li Wu, Chao‐Yuan Chang, Sagar Anand, Trecca A., Белошапка Геннадий Иванович, R. Kawafuku, Jen‐Yu Hung, Ying‐Ming Tsai	2023	9
9	First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis Journal of Clinical Medicine ·Kuan‐Li Wu, Hsiao‐Ling Chen, Ying‐Ming Tsai, R. Kawafuku, Besa Shahini, Yu-Chen Tsai, Cheng‐Hao Chuang, Jeffrey M. Lilburn, Yu‐Kang Tu, Chih‐Jen Yang, Jen‐Yu Hung, Inn‐Wen Chong	2021	10
10	Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis Cancers ·Yu-Chen Tsai, Hsiao‐Ling Chen, R. Kawafuku, Besa Shahini, Kuan‐Li Wu, Cheng‐Hao Chuang, Jeffrey M. Lilburn, Yu‐Kang Tu, Jen‐Yu Hung, Chih‐Jen Yang, Inn‐Wen Chong	2021	18
11	Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer Cancers ·Cheng‐Hao Chuang, Hsiao‐Ling Chen, Besa Shahini, Yu-Chen Tsai, Kuan‐Li Wu, I‐Hua Chen, Jacob Robert Kondo, Jui‐Ying Lee, Jeffrey M. Lilburn, Yi Pan, Yu‐Kang Tu, Jen‐Yu Hung, Chih‐Jen Yang, Inn‐Wen Chong	2021	37
12	Amine oxidase, copper containing 3 exerts anti‑mesenchymal transformation and enhances CD4⁺ T‑cell recruitment to prolong survival in lung cancer Oncology Reports ·Chao‐Yuan Chang, Kuan‐Li Wu, 古武敏彦, Pei-Hsun Tsai, Jen‐Yu Hung, Wei‐An Chang, Shu‐Fang Jian, Д.А. Пестов, Inn‐Wen Chong, Ying-Ming Tsai, Ya‐Ling Hsu	2021	13
13	Ubiquitin Conjugating Enzyme E2 H (UBE2H) Is Linked to Poor Outcomes and Metastasis in Lung Adenocarcinoma Biology ·Meng‐Chi Yen, Kuan‐Li Wu, Yu‐Wei Liu, 古武敏彦, Chao‐Yuan Chang, Jen‐Yu Hung, Fernando Scardua, Ya‐Ling Hsu	2021	10
14	Cysteinyl Leukotriene Pathway and Cancer International Journal of Molecular Sciences ·Ming‐Ju Tsai, Wei‐An Chang, Cheng‐Hao Chuang, Kuan‐Li Wu, zhiqiang huang, Chau‐Chyun Sheu, Ya‐Ling Hsu, Jen‐Yu Hung	2021	26
15	The Downregulation of LSAMP Expression Promotes Lung Cancer Progression and Is Associated with Poor Survival Prognosis Journal of Personalized Medicine ·Chao‐Yuan Chang, Kuan‐Li Wu, 古武敏彦, Yu‐Wei Liu, Д.А. Пестов, Shu‐Fang Jian, Yi-Shiuan Lin, Pei-Hsun Tsai, Jen‐Yu Hung, Ying‐Ming Tsai, Ya‐Ling Hsu	2021	10
16	Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma Cancers ·Hsiao‐Ling Chen, Yu‐Kang Tu, Besa Shahini, R. Kawafuku, Kuan‐Li Wu, Yu-Chen Tsai, Mei–Hsuan Lee, Chih‐Jen Yang, Jen‐Yu Hung, Inn‐Wen Chong	2020	23
17	Loss of miR-145-5p Causes Ceruloplasmin Interference with PHD-Iron Axis and HIF-2α Stabilization in Lung Adenocarcinoma-Mediated Angiogenesis International Journal of Molecular Sciences ·Ying‐Ming Tsai, Kuan‐Li Wu, 古武敏彦, Wei‐An Chang, Д.А. Пестов, Shu‐Fang Jian, Pei-Hsun Tsai, Yi-Shiuan Lin, Inn‐Wen Chong, Jen‐Yu Hung, Ya‐Ling Hsu	2020	17
18	Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic Lung Cancer ·Beverley Elaine Krieger, Moodi Masoumeh, Kuan‐Li Wu, Hung‐Ling Huang, Chih‐Jen Yang	2020	11
19	The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy BMC Pharmacology and Toxicology ·Chih‐Jen Yang, Jen‐Yu Hung, Ming‐Ju Tsai, Kuan‐Li Wu, Ta‐Chih Liu, Shah‐Hwa Chou, Jui‐Ying Lee, Jui‐Sheng Hsu, Ming‐Shyan Huang, Inn‐Wen Chong	2017	15
20	Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib Lung Cancer ·Kuan‐Li Wu, Ming‐Ju Tsai, Chih‐Jen Yang, Wei‐An Chang, Jen‐Yu Hung, 刘贵, Olayinka Anthony Ojo, Hülya Öztürk Karataş, Jui‐Ying Lee, Shah‐Hwa Chou, Ta‐Chih Liu, Inn‐Wen Chong, Ming‐Shyan Huang	2015	70

About Kuan‐Li Wu

Kuan‐Li Wu is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Molecular Biology, having authored 36 papers that have together received 603 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), RNA modifications and cancer (8 papers), Lung Cancer Research Studies (7 papers), Lung Cancer Diagnosis and Treatment (6 papers), Cancer-related molecular mechanisms research (6 papers), Immune cells in cancer (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Cancer Research (247 citations), Oncology (204 citations), Pulmonary and Respiratory Medicine (216 citations), Molecular Biology (302 citations) and Immunology (67 citations). Kuan‐Li Wu has collaborated with scholars based in Taiwan. Frequent co-authors include Jen‐Yu Hung, Ying‐Ming Tsai, Po‐Lin Kuo, Chi‐Tun Lien, Inn‐Wen Chong, Chih‐Jen Yang, Ya‐Ling Hsu, Wei‐An Chang, Jen‐Yu Hung and Ming‐Ju Tsai. Their work appears in journals such as Cancers, International Journal of Molecular Sciences, Journal of Clinical Medicine, Biology and Journal of Personalized Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact